granted marketing authorization for an updated formulation of Moderna’s COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1, for individuals six months and older. See Also ...

Moderna swung to a loss in the last three months of the year after an early launch of its updated Covid-19 vaccine shifted sales out of the fourth quarter.

A member of the U.K. Parliament is calling for regulators to audit pharmaceutical companies that have made misleading ...

Moderna (NASDAQ:MRNA) stock drops ~5% as its Q4 2024 results show revenue beat but earnings miss expectations. Read more here ...

1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. About Moderna Moderna is a leader in the creation of the field of mRNA medicine.